{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:45:13Z","timestamp":1786243513632,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clineuro.2026.109497","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:33:20Z","timestamp":1779305600000},"page":"109497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lymphopenia predicts infectious complications after alemtuzumab therapy in multiple sclerosis: Real-world experience from a Brazilian cohort"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-9464","authenticated-orcid":false,"given":"Alexandre Mestre","family":"Tejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Ces\u00e1rio","family":"de Holanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarso","family":"Adoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Lu\u00edsa Ap\u00f3stolos","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Coracini","family":"Tonacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clineuro.2026.109497_bib1","article-title":"Alemtuzumab for multiple sclerosis","volume":"6","author":"Riera","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10422","key":"10.1016\/j.clineuro.2026.109497_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clineuro.2026.109497_bib3","volume":"2020","author":"Multiple Sclerosis International Federation","year":"2025"},{"key":"10.1016\/j.clineuro.2026.109497_bib4","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109497_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40263-024-01066-3","article-title":"Real-world retrospective analysis of alemtuzumab outcomes in relapsing-remitting multiple sclerosis: The LEMCAM Study","volume":"38","author":"Costa-Frossard Fran\u00e7a","year":"2024","journal-title":"CNS Drugs"},{"issue":":S3-9","key":"10.1016\/j.clineuro.2026.109497_bib6","article-title":"A personal history of the CAMPATH-1H antibody","volume":"19","author":"Waldmann","year":"2002","journal-title":"Med Oncol."},{"issue":"4","key":"10.1016\/j.clineuro.2026.109497_bib7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.clineuro.2026.109497_bib8","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.clineuro.2026.109497_bib9","series-title":"Lemtrada: EPAR \u2013 Product information","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.clineuro.2026.109497_bib10","series-title":"Lemtrada (alemtuzumab) injection: prescribing information","author":"U.S. Food and Drug Administration","year":"2014"},{"issue":"9856","key":"10.1016\/j.clineuro.2026.109497_bib11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.clineuro.2026.109497_bib12","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clineuro.2026.109497_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1212\/WNL.0b013e31827b5927","article-title":"Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis","volume":"80","author":"Cossburn","year":"2013","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.clineuro.2026.109497_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz445","article-title":"Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 Surface Antigens","volume":"6","author":"Zappulo","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.clineuro.2026.109497_bib15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clineuro.2018.11.002","article-title":"Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature","volume":"175","author":"Maniscalco","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.clineuro.2026.109497_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.msard.2018.04.014","article-title":"Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion","volume":"23","author":"Yiannopoulou","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109497_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s13104-019-4507-6","article-title":"Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis","volume":"12;12","author":"Holm\u00f8y","year":"2019","journal-title":"BMC Res Notes"},{"issue":"10","key":"10.1016\/j.clineuro.2026.109497_bib18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/14740338.2021.1942454","article-title":"Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies","volume":"20","author":"Buonomo","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"issue":"12","key":"10.1016\/j.clineuro.2026.109497_bib19","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/1352458518796675","article-title":"Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study","volume":"25","author":"Wray","year":"2019","journal-title":"Mult. Scler."},{"issue":"11","key":"10.1016\/j.clineuro.2026.109497_bib20","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"CAMMS223, CAMMS03409, and TOPAZ Investigators. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109497_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231194823","article-title":"Safety and efficacy with alemtuzumab over 13\u2009years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","volume":"16","author":"Coles","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2026.109497_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104762","article-title":"Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort","volume":"75","author":"L\u00f3pez-Real","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.clineuro.2026.109497_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7224\/1537-2073.2018-076","article-title":"Effect of Alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis","volume":"22","author":"Chinea","year":"2020","journal-title":"Int J. MS Care"},{"key":"10.1016\/j.clineuro.2026.109497_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103814","article-title":"Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20\/CD52 agents for multiple sclerosis","volume":"63","author":"Zappulo","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.clineuro.2026.109497_bib25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00415-025-13473-7","article-title":"Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR)","volume":"272","author":"Monschein","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2026.109497_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103780","article-title":"Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia","volume":"61","author":"B\u00f3nitto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109497_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3988\/jcn.2019.15.3.328","article-title":"Therapeutic outcome of alemtuzumab in korean patients with multiple sclerosis: 2-Year Follow-Up","volume":"15","author":"Hyun","year":"2019","journal-title":"J. Clin. Neurol."},{"issue":"8","key":"10.1016\/j.clineuro.2026.109497_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2021.1918673","article-title":"Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review","volume":"20","author":"Scotto","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109497_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1352458518813110","article-title":"Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis","volume":"26","author":"Russo","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clineuro.2026.109497_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.msard.2017.03.001","article-title":"Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis","volume":"14","author":"Yann","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2026.109497_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101503","article-title":"Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis","volume":"38","author":"Lau","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109497_bib32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/1744666X.2021.1886924","article-title":"Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment","volume":"17","author":"Otero-Romero","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109497_bib33","article-title":"Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study","volume":"8","author":"Zingaropoli","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.clineuro.2026.109497_bib34","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Secretaria de Vigil\u00e2ncia em Sa\u00fade. Departamento do Programa Nacional de Imuniza\u00e7\u00f5es. Estrat\u00e9gia de Vacina\u00e7\u00e3o contra a Covid-19 \u2013 2. ed. \u2013 Bras\u00edlia: Minist\u00e9rio da Sa\u00fade, 2024. 46 p.: il."},{"key":"10.1016\/j.clineuro.2026.109497_bib35","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.15585\/mmwr.mm7349a2","article-title":"Use of Additional Doses of 2024\u20132025 COVID-19 Vaccine for Adults Aged \u226565 Years and Persons Aged \u22656 months with moderate or severe immunocompromise: recommendations of the advisory committee on immunization practices \u2014 United States, 2024","volume":"73","author":"Roper","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.clineuro.2026.109497_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaf395","article-title":"Real-world effectiveness of the adjuvanted recombinant zoster vaccine in \u226550-year-old adults with autoimmune diseases","author":"Constenla","year":"2025","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/j.clineuro.2026.109497_bib37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0b013e3182a35215","article-title":"Immune competence after alemtuzumab treatment of multiple sclerosis","volume":"81","author":"McCarthy","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2026.109497_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102439","article-title":"Effects of MS disease-modifying therapies on responses to vaccinations: A review","volume":"45","author":"Ciotti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.clineuro.2026.109497_bib39","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/ene.16015","article-title":"The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies","volume":"30","author":"Rabenstein","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109497_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3390\/pathogens14030235","article-title":"Extensive T-Cell Profiling Following SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with DMTs","volume":"14","author":"Solchenberger","year":"2025","journal-title":"Pathogens"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726001897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726001897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:24:47Z","timestamp":1786242287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846726001897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0303846726001897"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109497","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphopenia predicts infectious complications after alemtuzumab therapy in multiple sclerosis: Real-world experience from a Brazilian cohort","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109497"}}